01重点学术场次Priority Sessions4 场
本专题的重点场次包含 Hot Line、LBCS、New ESC Guidelines、Ask the Trialists、Guidelines in Practice、Great Debates 等。
顽固性与继发性高血压1 场
LBCS
晚期临床科学：肾素-血管紧张素-醛固酮通路抑制
Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition
非奈利酮治疗高血压肾病的疗效
Effects of finerenone in patients with hypertensive nephropathy
KARDINAL 试验延长随访：评估 tonlamarsen 治疗未控制高血压的效应
Extended Follow-Up of the KARDINAL Trial Assessing the Effect of Tonlamarsen in Uncontrolled Hypertension
抑制醛固酮比降压更能逆转原发性醛固酮增多症所致心脏重构：MATCH 与 PATHWAY-1 前瞻性 CMR 亚研究
Aldosterone suppression is more effective than blood pressure reduction in reversing cardiac remodelling due to primary aldosteronism: the MATCH and PATHWAY-1 prospective CMR sub-studies
baxdrostat 治疗未控制或难治性高血压的长期疗效与安全性：BaxHTN 3 期试验结果
Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial
非奈利酮治疗慢性肾脏病合并心血管疾病患者的疗效与安全性：个体患者数据汇总分析（INFINITY）
Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)
AI 与数字技术1 场
Great Debates
焦点辩论：无袖带血压、AI 应用与聊天机器人会成为高血压管理主力吗
Great Debate: cuffless blood pressure measurements, artificial intelligence-based apps, and chatbots will become the mainstay of hypertension care
无袖带血压、AI 应用与聊天机器人将成为高血压管理主力
Cuffless blood pressure measurements, artificial intelligence-based apps, and chatbots will become the mainstay of hypertension care
正方Yida Tang北京大学第三医院中国反方Eugene YangUniversity of Washington评论员Isabella SudanoUniversity Hospital Zurich
盐替代与生活方式1 场Hot Line 1
Hot Line
HOT LINE 9（全球首发专场）
HOT LINE 9
SHASTA-3/4 研究 12 个月结果
SHASTA-3/4 12-Month Results
CRHCP：长期血压控制与痴呆风险
CRHCP: Long-Term Blood Pressure Control and Dementia Risk
贯穿心血管风险谱的降压治疗
Blood Pressure-Lowering Treatment Across the Spectrum of Cardiovascular Risk
ECLIPSE-CKD：慢性肾脏病中的盐替代品
ECLIPSE-CKD: Salt Substitute in Chronic Kidney Disease
血压测量与数字管理1 场
LBCS
晚期临床科学：高血压
Late-Breaking Clinical Science: hypertension
沙库巴曲/阿利沙坦联合氨氯地平治疗单药控制不佳高血压患者的疗效与安全性：SALUS 研究
Efficacy and safety of sacubitril/allisartan plus amlodipine in hypertensive patients not adequately controlled by amlodipine or sacubitril/allisartan monotherapy: the SALUS study
ELFIE-HYPERTENSION 试验：AI 增强与游戏化移动健康干预管理高血压的国际随机多中心试验
The ELFIE-HYPERTENSION Trial: An international randomized multicenter trial of an artificial intelligence enhanced and gamified mobile health intervention for hypertension management
AI 增强应用与可穿戴设备管理血压：My Intelligent Cardiac Assistant（MICArdiac）随机对照试验
Blood pressure management with an artificial intelligence-enhanced app and wearable devices: My Intelligent Cardiac Assistant (MICArdiac) Randomised Controlled Trial
化学依从性检测引导的干预在管理降压治疗不依从中具有成本效益——OUTREACH 研究终生评估
Chemical adherence testing-guided intervention is cost-effective in management of non-adherence to antihypertensive treatment - life-time evaluation of OUTREACH Study
02中国专家参与场次China Faculty3 场
| 中国专家参与的报告 |
|---|
| AI 与数字技术 · 1 项中国专家报告 |
无袖带血压测量、AI 应用与聊天机器人将成为高血压诊疗主流：正方 Cuffless blood pressure measurements, artificial intelligence-based apps, and chatbots will become the mainstay of hypertension care: pro |
| 盐替代与生活方式 · 2 项中国专家报告 |
CRHCP：长期血压控制与痴呆风险 CRHCP: Long-Term Blood Pressure Control and Dementia Risk |
ECLIPSE-CKD：慢性肾脏病中的盐替代品 ECLIPSE-CKD: Salt Substitute in Chronic Kidney Disease |
| 血压测量与数字管理 · 1 项中国专家报告 |
沙库巴曲/阿利沙坦联合氨氯地平治疗单药控制不佳高血压患者的疗效与安全性：SALUS 研究 Efficacy and safety of sacubitril/allisartan plus amlodipine in hypertensive patients not adequately controlled by amlodipine or sacubitril/allisartan monotherapy: the SALUS study |
03本领域中国研究China Abstracts18 篇
| 研究标题 | 第一作者 | 所在机构 |
|---|---|---|
| 血压测量 · 5 篇 | ||
检测高血压人群运动诱发的血压异常升高 Detecting abnormal exercise-induced high blood pressure in hypertension | Liwen Bao | 华山医院 |
收缩压与生命八要素双轨迹与胃肠癌及全因死亡：前瞻性队列研究 Dual-trajectories of systolic blood pressure and life’s essential 8 with gastrointestinal cancer and all-cause mortality: a prospective cohort study | Heng Yu | 兰州大学第二医院 |
收缩压超负荷：维持性血液透析患者心血管死亡的新预测因子 SBP-hyper-burden: a novel predictor of cardiovascular mortality in patients undergoing maintenance hemodialysis | Jiamin Tang | 上海市第十人民医院 |
户外温度是否改变24小时动态收缩压的预后价值？IDACO研究 Does outdoor temperature modify the prognostic value of 24-hour ambulatory systolic blood pressure? the IDACO Study | Yuchen Wang | 上海市第一人民医院 |
246,401例未治疗高血压成人高血压表型的全球与区域年龄性别模式：三项五月测量月活动（2021-2023）的横断面分析 Global and regional patterns in hypertension phenotypes by age and sex among 246,401 untreated hypertensive adults: a cross-sectional analysis of three May Measurement Month campaigns (2021-2023) | Xiting Wang | 北京大学第一医院 |
| 预防 · 3 篇 | ||
从青年到中年的尿酸水平与高血压发病风险 Uric acid from young adulthood to middle age and risk of hypertension | Jia-Jie Wang | 同济大学附属同济医院 |
GRK4遗传变异与中国成人盐敏感性血压变化及高血压发病的关联 Association of genetic variations in GRK4 with salt-sensitive, blood pressure changes and hypertension incidence in Chinese adult | Guilin Hu | 西安交通大学第一附属医院 |
孕前血清尿酸与体外受孕女性不良妊娠结局的关联 Association of serum uric acid during pre-pregnancy with adverse pregnancy outcomes among women conceived by in-vitro fertilization | Shaomin Chen | 北京大学第三医院 |
| 临床 · 2 篇 | ||
原发性醛固酮增多症的局部血脑屏障通透性与脑微出血相关 Regional blood-brain barrier permeability is associated with cerebral microbleeds in primary aldosteronism | Naifang Cao | 华山医院 |
长期血压管理中的J型曲线趋势：STEP试验老年高血压患者的治疗达标时间 J-Curve trend in long-term blood pressure management: time in therapeutic range among elderly hypertensive patients from the STEP trials | Qiaoxi Yang | 中国医学科学院北京协和医学院阜外医院 |
| 靶器官损害与左心室肥厚 · 2 篇 | ||
中年期血压变化与亚临床靶器官损害 Blood pressure change and subclinical target organ damage in mid-adulthood | Tongshuai Guo | 西安交通大学第一附属医院 |
运动诱导的FXYD2上调经PARP1/myocardin轴预防Ang II高血压中血管平滑肌细胞表型转换与血管重构 Exercise-induced FXYD2 upregulation prevents VSMC phenotypic switching and vascular remodeling in Ang II-induced hypertension through PARP1/myocardin axis | Haiyi Yu | 北京大学第三医院 |
| 药物治疗 · 2 篇 | ||
强化降压在不同程度肾功能损害人群中的效果：ESPRIT试验事后分析 Effects of intensive blood pressure control across the spectrum of renal impairment: a post hoc analysis from ESPRIT | Shitian Li | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
GLP-1受体激动剂对新发高血压年轻超重/肥胖患者血压的影响：多中心真实世界前瞻性队列研究 Effects of GLP-1 RAs on blood pressure in young overweight/obese patients with new-onset hypertension: a multicenter, real-world prospective cohort study | Yi Zhang | 上海市第十人民医院 |
| 流行病学、预后与结局 · 2 篇 | ||
基于估计脉搏波传导速度的难治性高血压患者死亡风险分层：NHANES 1999-2020队列的启示 Risk stratification for mortality in patients with refractory hypertension based on estimated pulse wave velocity: insights from the nhanes 1999-2020 cohort | Wei Bao | 同济大学附属同济医院 |
遗传共定位与单细胞转录组证据关联肠易激综合征与血压调控 Genetic colocalization and single-cell transcriptomic evidence link irritable bowel syndrome to blood pressure regulation | Guo-Liang Li | 西安交通大学第一附属医院 |
| 继发性高血压 · 1 篇 | ||
原发性醛固酮增多症与原发性高血压的代谢与炎症表型差异：倾向评分匹配队列研究 Metabolic and inflammatory phenotypic divergence between primary aldosteronism and essential hypertension: a propensity score-matched cohort study | Tong Liu | 天津医科大学第二医院 |
| 生活方式干预 · 1 篇 | ||
基层医疗50万高血压患者的可改变危险因素与心血管疾病5年及终生风险 Modifiable risk factors and 5-year and lifetime risks of cardiovascular disease among 0.5 million hypertensive patients in primary care | Jiangshui Wang | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
04企业卫星会Industry Symposia7 个系列
赞助商分布10 场 · AstraZeneca 4 场 · Medtronic 1 场 · Boehringer Ingelheim 1 场 · Mineralys 1 场 · Servier
肾去神经（RDN）1 个系列
Medtronic
对话肾动脉消融专家（系列共 3 场）
Meet the renal denervation expert
对话肾去神经专家
Meet the renal denervation expert
女性与性别差异1 个系列
Mineralys
女性高血压：是时候回应未被满足的临床需求
Hypertension in women: time to address the unmet clinical need
欢迎与介绍：女性高血压、肥胖与醛固酮——脂肪细胞失调的作用
Welcome and introduction to hypertension, obesity, and aldosterone in women - role of adipocyte dysregulation
女性高血压与心-肾-代谢综合征风险：未被满足的临床需求
Hypertension and cardio-renal-metabolic syndrome risk in women: unmet clinical need
高血压的性别二态性：性激素与醛固酮的相互作用
Sexual dimorphism of hypertension: interplay between sex hormones and aldosterone
治疗下高血压仍持续控制不佳——病例讨论
Persistent sub-optimal control of hypertension despite treatment - case-based panel discussion
女性高血压：是时候解决未被满足的临床需求——问答与闭幕致辞
Hypertension in women: time to address the unmet clinical need - Q&A and closing remarks
综合与其他5 个系列
AstraZeneca
专家门诊：难控性高血压的优化管理实用策略（系列共 9 场）
Expert clinic: practical strategies for optimising management of uncontrolled hypertension
欢迎致辞
Welcome
识别与管理未控制高血压的最佳实践
Best practices to identify and manage uncontrolled hypertension
醛固酮是高血压管理中被遗漏的一环吗？
Is aldosterone the missing link in managing hypertension?
高血压患者全病程的敏捷决策
Agile decision making across the hypertension patient journey
专家答疑
Ask the experts
总结与闭幕
Summary and close
Boehringer Ingelheim
检测、发现、关联：白蛋白尿检测在心血管照护中的作用
Test, detect, connect: the role of albuminuria testing in cardiovascular care
欢迎与介绍：尿白蛋白/肌酐比值检测用于心血管风险检测与管理的理由
Welcome and introduction: the case for urine albumin-to-creatinine ratio testing in cardiovascular risk detection and management
为什么白蛋白尿作为血管损伤标志物很重要？
Why does albuminuria matter as a marker of vascular damage?
白蛋白尿如何影响心衰风险与临床管理？
How does albuminuria influence heart failure risk and clinical management?
白蛋白尿对高血压管理及更广泛的意义是什么？
What does albuminuria mean for hypertension management and beyond?
检测、发现、连接：利用尿白蛋白/肌酐比值检测应对心血管疾病——专家讨论与问答
Test, detect, connect: harnessing urine albumin-to-creatinine ratio testing in cardiovascular conditions - Panel discussion and Q&A
闭幕致辞
Closing remarks
Medtronic
高血压管理进阶：证据落地日常实践
Advancing hypertension care: applying evidence in daily practice
弥合血压治疗差距——今天有哪些选择
Closing the gap in blood pressure treatment - what options are available today
从指南到实践：识别合适的肾去神经患者
Guidelines to practice: identifying the right renal denervation patient
高危心血管患者的肾动脉去神经术：通往更好诊疗之路？
Renal denervation in high cardiovascular risk patients: a way to better care?
管理高血压患者
Managing the hypertensive patient
从证据到执行：建设你的肾去神经项目
From evidence to execution: building your renal denervation programme
推进高血压诊疗：将证据应用于日常实践——讨论与总结
Advancing hypertension care: applying evidence in daily practice - Discussion and conclusion
Servier
高血压的第四种药物之问
The fourth drug question in hypertension
第四个药物问题背后的患者
The patient behind the fourth drug question
第一：打破高危患者控制不佳的循环
First: breaking the cycle of poor control in high-risk patients
其二：依从性——房间里的大象
Second: adherence: the elephant in the room
其三：为何全面阻断很重要？
Third: why comprehensive blockade matters?
第四：单片复方制剂的力量
Fourth: the power of doing more with one-single-pill
第四个药物问题的答案
The fourth drug question answered
AstraZeneca
24小时血压负荷：醛固酮、心肾风险与新一代血压管理
24-hour blood pressure burden: aldosterone, cardiorenal risk, and the next generation of blood pressure control
欢迎、介绍、项目框架与目标回顾
Welcome, introduction, program framing, review of objectives
醛固酮与 24 小时血压负荷
Aldosterone and the 24-hour blood pressure burden
动态血压监测检出的难治性高血压 24 小时血压表型
Ambulatory blood pressure monitoring‑detected 24‑hour blood pressure phenotypes in resistant hypertension
靶向醛固酮：动态血压监测研究告诉我们醛固酮合酶抑制的什么信息
Targeting aldosterone: what ambulatory blood pressure monitoring studies tell us about aldosterone synthase inhibition
从 24 小时血压到心肾结局与未来方向
From 24‑hour blood pressure to cardiorenal outcomes and future directions
24 小时血压负荷：醛固酮、心肾风险与下一代血压控制——问答环节
24-hour blood pressure burden: aldosterone, cardiorenal risk, and the next generation of blood pressure control - Q&A
企业卫星会内容由赞助方支持，此处仅作学术日程信息陈列，不代表编辑立场。